Semax

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its front end mirrors the ACTH(4-7) fragment of adrenocorticotropic hormone, and a stabilizing Pro-Gly-Pro tail is attached to the end, which is why it is often described loosely as an ACTH(4-10) analog. It was developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences, associated with the groups of Ivan Ashmarin and Nikolai Myasoedov. Although it borrows a piece of a stress hormone, the added tail strips away the corticotropic, hormone-releasing activity, leaving a compound studied mainly for effects on the brain rather than the adrenal glands. In Russia it moved into clinical use for stroke, transient ischemic attack, and cognitive disorders, and it later spread through the wider nootropic community as a research-only peptide.

The most common reason people look into Semax is cognitive performance, with users reporting sharper focus, better memory and recall, and reduced mental fatigue or brain fog. Its original clinical context was neuroprotection and recovery, so it has been studied and used in Russia around ischemic stroke, transient ischemic attack, and traumatic brain injury. Because it is reported to nudge dopamine and serotonin signaling, some people also reach for it for mood, motivation, and a sense of calm alertness without the jitteriness of stimulants. Less mainstream uses discussed by clinicians include ADHD support, chronic fatigue, and optic nerve conditions, though evidence for these is thinner. It is frequently stacked with Selank, a related Russian anxiolytic peptide, with the pairing framed as focus plus a calmer baseline.

Semax is best known for raising brain-derived neurotrophic factor, or BDNF, a signaling protein tied to neuron growth, survival, and plasticity, and it appears to increase expression of BDNF and its receptor in brain regions such as the hippocampus and hypothalamus. Beyond that, it is described as modulating dopaminergic and serotonergic systems, which fits its reported effects on focus and mood. Clinicians also point to secondary actions including improved cerebral blood flow and antioxidant, anti-inflammatory protection of neural tissue. It is thought to interact with melanocortin receptors, possibly as a partial agonist or antagonist, and to inhibit enkephalin-degrading enzymes, which would prolong the action of the body’s own regulatory peptides. What makes it unusual is this layered, multi-target profile from a very small molecule, though the precise contribution of each pathway in humans is not fully pinned down.

Semax is most often used intranasally as drops or a spray, which is the route tied to its Russian clinical history and which places it close to the brain. Subcutaneous injection is the other route people describe, and it is generally less popular than the nasal form. Reported protocols frame it as a fairly short-acting compound, with some users noting effects within roughly fifteen to thirty minutes of a nasal dose and repeating it once to several times across a day depending on the person. Because tolerance to receptor-active compounds can build, commentators often describe cycling patterns such as several days on followed by a break, rather than continuous long-term use. These dosing patterns are description, not medical guidance, and clinicians stress that intranasal delivery near the brain makes product sourcing and purity an especially serious concern.

The great majority of Semax research is Russian, spanning animal models and clinical use, and much of it centers on ischemic stroke, brain injury, and cognitive impairment rather than healthy-brain enhancement. Mechanistic work supporting the BDNF and neurotrophin story is reasonably developed in animal studies, but rigorous, independent Western clinical trials are limited. Educators reviewing the compound repeatedly note that the human evidence, especially for the everyday focus and productivity use that drives its popularity, is thinner than the enthusiasm around it. Reported tolerability is good, with both Semax and its common partner Selank described as well tolerated and low in side effects in the available data. It is an intriguing, plausibly neuroprotective peptide whose strongest evidence sits in a specific clinical setting concentrated in one country, and whose nootropic reputation rests heavily on user reports.

Semax is approved and marketed as a medicine in Russia, where it is used clinically and appears on the country’s list of essential drugs. It is not approved by the FDA in the United States, and it is not an established pharmaceutical in most Western markets, so it typically circulates as a research-only chemical sold for laboratory use rather than as a licensed drug. That research-only framing is exactly why clinicians caution against buying and self-administering it, and why sourcing and purity are recurring worries given the intranasal route. It is sometimes encountered under names or codes tied to its ACTH-fragment origin, and its close relative Selank is often discussed alongside it.